DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

Information source: Northwestern University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Metastatic Breast Cancer

Intervention: Cyclosporins (Drug); nab-paclitaxel (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Northwestern University

Official(s) and/or principal investigator(s):
William Gradishar, MD, Principal Investigator, Affiliation: Northwestern University

Summary

The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.

Clinical Details

Official title: A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

To evaluate the safety, tolerability and feasibility of the combination of Cyclosporine A and nab-paclitaxel in the treatment of metastatic breast cancer (MBC).

To determine the maximum-tolerated dose (MTD) of Cyclosporine A and nab-paclitaxel in patients.

Secondary outcome: To describe any preliminary evidence of efficacy of Cyclosporine A and nab-paclitaxel in combination in patients.

Detailed description: Treatment for metastatic breast cancer commonly involves the use of the chemotherapy drug nab-paclitaxel. Nab-paclitaxel is a special preparation of paclitaxel inside a protein layer of albumin. Other studies have shown Cyclosporine A (CsA) may block the progression of advanced breast cancer. The combination of nab-paclitaxel and CsA is considered investigational which means it has not been approved by the US Food and Drug Administration, FDA. Participants on this study will receive nab-paclitaxel through a vein in the arm weekly 3 weeks out of 4, in the outpatient clinic. On the same day as the first infusion of nab-paclitaxel, participants will begin taking CsA tablets twice a day by mouth. Participants will continue to receive study treatment as long as their tumor responds. If the tumor does not respond or the participant experience severe side effects from study treatment, she will be removed from the study and offered other therapies, if that is appropriate.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria

- Female or male patients with adenocarcinoma of the breast with metastatic disease.

- Patients may have evaluable or measurable disease.

- Age > 18 years.

- Women of child-bearing potential and men must agree to use adequate contraception

(hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

- Able to swallow and retain oral medication.

Exclusion Criteria

- Patients who have had any major surgery, hormonal therapy (other than replacement),

chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Prior nab-paclitaxel is allowed.

- Patients may not be receiving any other investigational agents or receiving

concurrent anticancer therapy.

- Patients with uncontrolled brain metastases or leptomeningeal disease or active

neurologic impairment.

- History of allergic reactions attributed to compounds of similar chemical or biologic

composition to Cyclosporine A or nab-paclitaxel.

- Pregnant or lactating (Cyclosporine A is excreted into breast milk) females

- Patients with GI tract disease resulting in an inability to take oral medication,

malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e. g., Crohn's, ulcerative colitis).

- HIV-positive patients are excluded since Cyclosporine A may result in further

immunosuppression

Locations and Contacts

Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois 60611, United States
Additional Information

Starting date: February 2010
Last updated: September 13, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017